Market Research Logo

Tourette Syndrome - Pipeline Review, H2 2016

Tourette Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Tourette Syndrome - Pipeline Review, H2 2016’, provides an overview of the Tourette Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
  • The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tourette Syndrome
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Tourette Syndrome Overview
Therapeutics Development
Pipeline Products for Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics under Development by Companies
Tourette Syndrome - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Tourette Syndrome - Products under Development by Companies
Tourette Syndrome - Companies Involved in Therapeutics Development
Catalyst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Psyadon Pharmaceuticals, Inc.
Reviva Pharmaceuticals Inc.
Synchroneuron Inc.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd
Tourette Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amfetamine + guanfacine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabenazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valbenazine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vigabatrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourettes Syndrome
Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette Syndrome in Children
Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115
Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette Syndrome in Children Ages 7-17
Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome
Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome
Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854
May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Tourette Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H2 2016
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H2 2016
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Tourette Syndrome - Pipeline by Synchroneuron Inc., H2 2016
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Tourette Syndrome - Dormant Projects, H2 2016
Tourette Syndrome - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Tourette Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report